FILINGS
| GSK 0001131399 | |||
|---|---|---|---|
| Filing Date | Form Type | Description | Document |
| 2026-02-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2026-02-02 | SC TO-T | SC TO-T | View Document |
| 2026-01-26 | 6-K | EUROPEAN COMMISSION APPROVES AREXVY FOR ADULTS 18+ | View Document |
| 2026-01-20 | SC TO-C | SC TO-C | View Document |
| 2026-01-20 | SC TO-C | SC TO-C | View Document |
| 2026-01-20 | 6-K | GSK TO ACQUIRE RAPT THERAPEUTICS | View Document |
| 2026-01-20 | 6-K | AGREEMENT ON CHANGES TO VIIV MINORITY SHAREHOLDING | View Document |
| 2026-01-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-01-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-01-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-01-07 | 6-K | EC APPROVAL OF SHINGRIX PFS | View Document |
| 2026-01-07 | 6-K | POSITIVE PHASE 3 DATA FOR GSK'S BEPIROVIRSEN | View Document |
| 2026-01-06 | 6-K | EXDENSUR APPROVED IN JAPAN | View Document |
| 2026-01-05 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2026-01-05 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2026-01-05 | 6-K | NUCALA FOR ADULTS WITH COPD APPROVED IN CHINA | View Document |
| 2025-12-23 | 6-K | GSK TO LOWER DRUG PRICES AND EXPAND ACCESS IN US | View Document |
| 2025-12-22 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-12-22 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-12-19 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-12-18 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-12-17 | 6-K | EXDENSUR (DEPEMOKIMAB ULLA) APPROVED BY US FDA | View Document |
| 2025-12-17 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-12-16 | 6-K | EXDENSUR (DEPEMOKIMAB) UK MHRA APPROVAL | View Document |
| 2025-12-16 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-12-15 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP | View Document |
| 2025-12-15 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-12-12 | 6-K | DEPEMOKIMAB RECEIVES POSITIVE CHMP OPINION | View Document |
| 2025-12-12 | 6-K | NUCALA RECEIVES POSITIVE CHMP OPINION FOR COPD | View Document |
| 2025-12-12 | 6-K | POSITIVE CHMP OPINION ON AREXVY FOR ALL ADULTS 18+ | View Document |
| 2025-12-12 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-12-11 | 6-K | BLUJEPA APPROVED IN US FOR GONORRHOEA INDICATION | View Document |
| 2025-12-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-12-11 | 6-K | BLOCK LISTING APPLICATION | View Document |
| 2025-12-11 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-12-10 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-12-10 | 6-K | GSK'227 US FDA ORPHAN DRUG DESIGNATION IN SCLC | View Document |
| 2025-12-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-12-09 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-12-08 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-12-05 | SCHEDULE 13D/A | View Document | |
| 2025-12-05 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-12-04 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-12-03 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-12-02 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-12-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-12-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-12-01 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-11-28 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-11-28 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-11-26 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-11-25 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-11-24 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-11-21 | 6-K | INITIATION OF LITIGATION AGAINST ANAPTYSBIO INC | View Document |
| 2025-11-21 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-11-20 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-11-19 | 6-K | TRANSFER OF TREASURY SHARES | View Document |
| 2025-11-19 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-11-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-11-18 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-11-17 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-11-14 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-11-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-11-13 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-11-12 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2025-11-12 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-11-12 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-11-10 | 6-K | GSK PUBLISHES PROVISIONAL DIVIDEND DATES | View Document |
| 2025-11-10 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-11-07 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-11-06 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-11-05 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-11-04 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-11-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-11-03 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-10-31 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-10-30 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-10-30 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-10-29 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-10-29 | 6-K | 3RD QUARTER RESULTS | View Document |
| 2025-10-28 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-10-28 | 6-K | GSK ADC GETS ORPHAN DRUG DESIGNATION IN THE EU | View Document |
| 2025-10-27 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-10-24 | 6-K | BLENREP APPROVED BY US FDA IN MULTIPLE MYELOMA | View Document |
| 2025-10-24 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-10-23 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-10-22 | 6-K | POSITIVE DATA FOR LOW CARBON VERSION VENTOLIN MDI | View Document |
| 2025-10-22 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-10-22 | 6-K | LATOZINEMAB DATA READ OUT | View Document |
| 2025-10-21 | 6-K | POSITIVE CHMP OPINION FOR GSK ON SHINGRIX PFS | View Document |
| 2025-10-21 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-10-21 | 6-K | GSK SHARE POSITIVE PH3 DATA ON TEBIPENEM HBR | View Document |
| 2025-10-20 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-10-17 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-10-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-10-16 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-10-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-10-15 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-10-14 | 6-K | GSK RECEIVES EXPANDED SHINGRIX APPROVAL IN CHINA | View Document |
| 2025-10-14 | 6-K | TRANSACTION IN OWN SHARES | View Document |
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.
